The medtech titan logged a series of legal wins this week.
Medtronic (NYSE:MDT) logged a series of legal wins this week after a federal judge dismissed a whistleblower lawsuit against the medtech titan and the U.S. Supreme Court declined to review a bid over legal fees in a long-running patent spat, upholding Medtronic’s victory from April last year.
In a lawsuit brought against Medtronic, Cavallino Consulting alleged that the medtech company defrauded government hospitals by overcharging them for the speedy delivery of medical equipment, without passing along required discounts.
U.S. district judge David Doty of Minneapolis ruled that the argument brought by Cavallino Consulting did not credibly allege that Medtronic engaged in “a broad and ongoing scheme to defraud,” and the judge pointed out that the complaint didn’t plausibly allege that Medtronic submitted any claims to the government, let alone fraudulent claims.
